Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/S3,152 enrolled

Overview

This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.

Study Type

OBSERVATIONAL

Enrollment

3,152

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with type 2 diabetes * Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment Exclusion Criteria: * Hypersensitivity (allergy) to liraglutide or to any of the excipients * Patient is participating in a clinical trial at the inclusion * Type 1 diabetes

Locations (1)

Novo Nordisk Investigational Site

Paris La Défense Cedex, France

Outcomes

Primary Outcomes

Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%

Time frame: Month 24

Secondary Outcomes

Change in HbA1c at month 3

Time frame: Month 0, Month 3

Change in HbA1c at month 6

Time frame: Month 0, Month 6

Change in HbA1c at month 12

Time frame: Month 0, Month 12

Change in HbA1c at month 18

Time frame: Month 0, Month 18

Change in HbA1c at month 24

Time frame: Month 0, Month 24

Change in fasting plasma glucose (FPG) at month 3

Time frame: Month 0, Month 3

Change in fasting plasma glucose (FPG) at month 6

Time frame: Month 0, Month 6

Change in fasting plasma glucose (FPG) at month 12

Time frame: Month 0, Month 12

Change in fasting plasma glucose (FPG) at month 18

Time frame: Month 0, Month 18

Change in fasting plasma glucose (FPG) at month 24

Time frame: Month 0, Month 24

Change in Body Weight at Month 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.